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Abstract 
The aims were (I) to describe a European lower risk MDS population and the use of 
erythropoietin stimulation agents (ESA), (II) to describe the AML population in Sweden 
1997-2006 with emphasis on secondary AML (s-AML) and therapy-related AML (t-
AML), (III) to investigate the use and effect of allogeneic hematopoietic stem cell 
transplantation (HSCT) in the AML population in Sweden 1997-2013, and (IV) to 
merge  patients from the Swedish AML Registry 2009-14 with patients from the 
Swedish MDS Registry 2009-14 in order to describe the patients with s-AML after MDS 
from time of MDS diagnosis and AML diagnosis. Patients, methods and results: (I) 
ESA treatment were given to 45.6% patients with lower risk MDS, median duration 
27.5 months. A propensity model, comparing ESA-treated and untreated was used. 
Median time to first post-ESA treatment transfusion was 6.1 months in patients 
transfused before ESA treatment compared to 23.3 months in non-transfused patients 
(p<0,0001), showing that ESAs can significantly delay the onset of a regular transfusion 
need in patients with lower-risk MDS. (II) Of 3,363 AML patients with induction 
therapy, 73.6% were de novo AML, 18.7% had antecedent hematological disease 
(AHD-AML), and 7.7% had t-AML. S-AML-patients were older compared to de novo 
AML and had higher cytogenetic risk scores. Multivariate analysis showed that AHD-
AML and t-AML were independent risk factors for inferior survival in the younger age 
groups. (III) Of 3337 intensively treated patients, 21% underwent HSCT at any stage of 
the disease. Five-year survival without and with allogeneic HSCT were 0% vs 50% for 
MPN-AML, 3% vs 39% for MDS-AML, 8% vs. 48% for t-AML and 24% vs. 57% for 
de novo AML-patients. Presence of any chronic graft versus host disease (cGvHD) 
compared to no cGvHD and a GvHD grade 1 or lower was significantly associated to 
better survival in a multivariable analysis. Allogeneic HSC is the only option for cure 
in S-AML. (IV)We found 257 patients with sufficient information from both AML and 
MDS registries for further examination. 72.2% had high risk cytogenetics and 66.8%, 
had performance status 0-1 at AML diagnosis. Median time from MDS diagnosis to 
AML diagnosis was 10.8 months. Median survival time for S-AML was 4.93 months. 
Allogeneic HSCT improves survival significantly in the younger age groups. 
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